Trial intelligence / Profile preview

MODUL: Biomarker-Driven Maintenance in First-Line mCRC

NCT02291289Phase 2Completed

Sponsor: Roche
Start: Apr 2015
Primary completion: May 2019
Modality: Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
Countries: 23

Overview

Phase 2, randomised, open-label trial of atezolizumab, vemurafenib, trastuzumab, pertuzumab, cobimetinib and 1 more in metastatic colorectal cancer (mCRC) (8 cohorts), sponsored by Roche. Primary endpoint: Progression-Free Survival at 5 years. Started Apr 2015; status: completed.

Drugs

atezolizumabvemurafenibtrastuzumabpertuzumabcobimetinib

Conditions

metastatic colorectal cancer (mCRC)

Beyond the preview

Go deeper on NCT02291289.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02291289.